Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers from across the Medical Sciences Division are working hard to combat the COVID-19 crises. With particular strengths in infectious diseases and international health, we are well placed to contribute to better understanding and effectively controlling the epidemic. We have a long history of responding to crises, in the UK and around the world and are leaders in emergency vaccine development. During the 2014 Ebola outbreak, our scientists performed the world’s first human Ebola vaccine studies, starting them before any other university or company. Our researchers, in collaboration with partners across the globe, are working to develop an effective vaccine and drugs to target this virus, and have already introduced innovative public health measures and collaborative online tools that are being used in hospitals here and abroad.

Coronavirus-related news from across the Medical Sciences Division

3,400 different medicines used globally to treat COVID-19

Insufficient data, and misleading recommendations led to significant early heterogeneity in global COVID-19 patient management, according to recent BMJ study.

Children and Adolescents’ Mental Health: One Year On

Parents and carers reported that behavioural, emotional and attentional difficulties in their children changed considerably throughout the past year, increasing in times of national lockdown and decreasing as restrictions eased and schools reopened, according to the latest Co-SPACE (COVID-19 Supporting Parents, Adolescents, and Children in Epidemics) study, led by experts at the University of Oxford.

Significant reductions in COVID-19 infections found after single dose of Oxford-AstraZeneca and Pfizer-BioNTech vaccine

COVID-19 infections fell significantly – by 65% - after a first dose of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines in this large community surveillance study.

National survey reveals big reductions in COVID-19 infections with single dose of Oxford-AZ and Pfizer vaccines

Data from the COVID-19 Infection Survey, a partnership between the University of Oxford, the Office of National Statistics (ONS) and the Department for Health and Social Care (DHSC), is the first to show the impact of vaccination on antibody responses and new infections in a large group of adults from the general population aged 16 years and older.

Research uncovers high risk to pregnant women from COVID-19

A study of more than 2,100 pregnant women across 18 countries worldwide has revealed that COVID-19 is associated with a higher risk of severe maternal and newborn complications than previously recognised.

Human challenge trial launches to study immune response to COVID-19

Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.